诊断学理论与实践 ›› 2024, Vol. 23 ›› Issue (03): 257-262.doi: 10.16150/j.1671-2870.2024.03.002
收稿日期:
2024-05-30
接受日期:
2024-06-19
出版日期:
2024-06-25
发布日期:
2024-06-25
通讯作者:
冯学兵 E-mail:xb.feng@163.com基金资助:
ZHANG Xin, ZHAO Shengnan, FENG Xuebing()
Received:
2024-05-30
Accepted:
2024-06-19
Published:
2024-06-25
Online:
2024-06-25
摘要:
系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种以多系统损害为特征的自身免疫性疾病。我国SLE患者基数大、病情重、缓解率低、复发率高、感染风险高。2023年,研究显示,全球有SLE患者约341万例,其中我国患者达70万~100万例,总数位居首位。我国SLE患者的平均发病年龄为30.7岁,女性与男性的发病比为12∶1;脏器受累更为多见,其中肾脏受累率为45.02%,血液系统受累率为37.2%,均显著高于欧洲SLE患者(肾脏受累率为27.9%,血液系统受累率为18.2%)。我国SLE患者疾病治疗的临床缓解率为2.47%,而国际报道的缓解率达22.9%。当前,我国SLE患者的短期生存率基本与国际一致(5年可达94%),但长期生存率仍不容乐观,呈断崖式下跌,25~30年生存率仅为30%。我国有84.13%的SLE患者使用糖皮质激素治疗,而国际上SLE患者的糖皮质激素使用率仅为42.6%,感染是我国SLE患者死亡的首位原因,而西方国家SLE患者死因则主要为心血管疾病和肿瘤。随着新分类标准的提出、达标治疗理念的引入、新型治疗方法的运用,将大大推动SLE诊疗的发展,有望进一步改善我国患者的预后。
中图分类号:
张昕, 赵盛楠, 冯学兵. 中国系统性红斑狼疮的诊治现状及挑战[J]. 诊断学理论与实践, 2024, 23(03): 257-262.
ZHANG Xin, ZHAO Shengnan, FENG Xuebing. Current status and challenges in diagnosis and treatment of systemic lupus erythematosus in China[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 257-262.
[1] | TEKTONIDOU M G, DASGUPTA A, WARD M M. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis[J]. Arthritis Rheumatol, 2016, 68(6):1432-1441. |
[2] |
TEKTONIDOU M G, LEWANDOWSKI L B, HU J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016[J]. Ann Rheum Dis, 2017, 76(12):2009-2016.
doi: 10.1136/annrheumdis-2017-211663 pmid: 28794077 |
[3] | 曾小峰, 李梦涛, 田新平. 中国系统性红斑狼疮发展报告2020[M]. 辽宁: 辽宁科学技术出版社, 2021. |
ZENG X F, LI M T, TIAN X P. Systemic lupus erythematosus in China: A national report of 2020[M]. Liaoning: Liaoning Science and Technology Press, 2021. | |
[4] | TIAN J, ZHANG D, YAO X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3):351-356. |
[5] |
LI M, WANG Y, ZHAO J, et al. Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus[J]. Rheumatol Immunol Res, 2021, 2(1):43-47.
doi: 10.2478/rir-2021-0001 pmid: 36467897 |
[6] |
TEKTONIDOU M G, WANG Z, DASGUPTA A, et al. Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011[J]. Arthritis Care Res (Hoboken), 2015, 67(8):1078-1085.
doi: 10.1002/acr.22575 pmid: 25732901 |
[7] |
FENG X, ZOU Y, PAN W, et al. Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China[J]. J Rheumatol, 2011, 38(7):1289-1295.
doi: 10.3899/jrheum.101088 pmid: 21459949 |
[8] | FENG X, PAN W, LIU L, et al. Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort[J]. PLoS One, 2016, 11(12):e0168619. |
[9] |
JIN Z, WANG F, PAN W, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus[J]. Rheumatology (Oxford), 2021, 60(4):1774-1783.
doi: 10.1093/rheumatology/keaa485 pmid: 33099642 |
[10] | FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6):736-745. |
[11] | LU W, TIAN F, MA J, et al. Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis[J]. Front Immunol, 2022, 13:1023451. |
[12] |
ADAMICHOU C, GENITSARIDI I, NIKOLOPOULOS D, et al. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(6):758-766.
doi: 10.1136/annrheumdis-2020-219069 pmid: 33568388 |
[13] | GLADMAN D, GINZLER E, GOLDSMITH C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39(3):363-369. |
[14] | YEE C S, SU L, TOESCU V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years[J]. Rheumatology (Oxford), 2015, 54(5):836-843. |
[15] | PETRI M, PURVEY S, FANG H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort[J]. Arthritis Rheum, 2012, 64(12):4021-4028. |
[16] |
LOPEZ R, DAVIDSON J E, BEEBY M D, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort[J]. Rheumatology (Oxford), 2012, 51(3):491-498.
doi: 10.1093/rheumatology/ker368 pmid: 22109798 |
[17] | BECKER-MEROK A, NOSSENT H C. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality[J]. J Rheumatol, 2006, 33(8):1570-1577. |
[18] | DING H, SHEN Y, HONG S M, et al. Biomarkers for systemic lupus erythematosus - a focus on organ damage[J]. Expert Rev Clin Immunol, 2024, 20(1):39-58. |
[19] | 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3):172-185. |
Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Chin J Intern Med, 2020, 59(3):172-185. | |
[20] |
YANG S C, LAI Y Y, HUANG M C, et al. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort[J]. Lupus, 2018, 27(11):1819-1827.
doi: 10.1177/0961203318792352 pmid: 30103646 |
[21] | VAN VOLLENHOVEN R F, BERTSIAS G, DORIA A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force[J]. Lupus Sci Med, 2021, 8(1):e000538. |
[22] |
VAN VOLLENHOVEN R, VOSKUYL A, BERTSIAS G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76(3):554-561.
doi: 10.1136/annrheumdis-2016-209519 pmid: 27884822 |
[23] | FLORIS A, PIGA M, PERRA D, et al. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage[J]. Arthritis Care Res (Hoboken), 2020, 72(12):1794-1799. |
[24] | PETRI M, MAGDER L S. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort[J]. Arthritis Rheumatol, 2018, 70(11):1790-1795. |
[25] | VAN VOLLENHOVEN R F, STOHL W, FURIE R A, et al. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study[J]. Lupus Sci Med, 2018, 5(1):e000288. |
[26] | FANOURIAKIS A, KOSTOPOULOU M, ANDERSEN J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update[J]. Ann Rheum Dis, 2024, 83(1):15-29. |
[27] | ROLAIN J M, COLSON P, RAOULT D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century[J]. Int J Antimicrob Agents, 2007, 30(4):297-308. |
[28] |
MOK C C, YING K Y, YIM C W, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up[J]. Ann Rheum Dis, 2016, 75(1):30-36.
doi: 10.1136/annrheumdis-2014-206456 pmid: 25550339 |
[29] | GINZLER E M, DOOLEY M A, ARANOW C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353(21):2219-2228. |
[30] | DOOLEY M A, JAYNE D, GINZLER E M, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis[J]. N Engl J Med, 2011, 365(20):1886-1895. |
[31] |
HUSSENBOCUS Y A A M, JIN Z, PAN W, et al. Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus[J]. Clin Rheumatol, 2022, 41(7):2043-2052.
doi: 10.1007/s10067-022-06117-y pmid: 35230560 |
[32] | FEI Y, SHI X, GAN F, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years[J]. Clin Rheumatol, 2014, 33(1):57-63. |
[33] | ILLESCAS-MONTES R, CORONA-CASTRO C C, MELGUIZO-RODRÍGUEZ L, et al. Infectious processes and systemic lupus erythematosus[J]. Immunology, 2019, 158(3):153-160. |
[34] |
NAVARRA S V, GUZMÁN R M, GALLACHER A E, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767):721-731.
doi: 10.1016/S0140-6736(10)61354-2 pmid: 21296403 |
[35] | FURIE R, ROVIN B H, HOUSSIAU F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis[J]. N Engl J Med, 2020, 383(12):1117-1128. |
[36] | ROVIN B H, FURIE R, TENG Y K O, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2):403-413. |
[37] |
Kidney Disease: Improving Global Outcomes KDIGO Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS[J]. Kidney Int, 2024, 105(1S):S1-S69.
doi: 10.1016/j.kint.2023.09.002 pmid: 38182286 |
[38] | CHEN R, FU R, LIN Z, et al. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study[J]. Lupus, 2023, 32(1):94-100. |
[39] | ROVIN B H, FURIE R, LATINIS K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study[J]. Arthritis Rheum, 2012, 64(4):1215-1226. |
[40] | MOUGIAKAKOS D, KRÖNKE G, VÖLKL S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus[J]. N Engl J Med, 2021, 385(6):567-569. |
[41] |
CARNEY E F. Treatment of SLE with anti-CD19 CAR-T cells[J]. Nat Rev Nephrol, 2022, 18(12):743.
doi: 10.1038/s41581-022-00651-3 pmid: 36323874 |
[42] | FURIE R, KHAMASHTA M, MERRILL J T, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus[J]. Arthritis Rheumatol, 2017, 69(2):376-386. |
[43] | FURIE R A, MORAND E F, BRUCE I N, ET AL. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4):e208-e219. |
[44] |
HE J, ZHANG X, WEI Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016, 22(9):991-993.
doi: 10.1038/nm.4148 pmid: 27500725 |
[45] |
HE J, ZHANG R, SHAO M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1):141-149.
doi: 10.1136/annrheumdis-2019-215396 pmid: 31537547 |
[46] | 中华医学会风湿病学分会, 中国医院协会临床新技术应用专业委员会. 异体间充质干细胞治疗系统性红斑狼疮专家共识[J]. 中华风湿病学杂志, 2022, 26(1):1-8. |
Rheumatology and Immunology branch of the Chinese Medical Association, New Clinical Technologies Application Professional Committee of China Hospital Association. Expert consensus on allogeneic mesenchymal stem cells in the treatment of systemic lupus erythematosus[J]. Chin J Rheumatol, 2022, 26(1):1-8. | |
[47] | WANG D, LI J, ZHANG Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study[J]. Arthritis Res Ther, 2014, 16(2):R79. |
[48] | YUAN X, QIN X, WANG D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients[J]. Nat Commun, 2019, 10(1):2498. |
[1] | 王一阳, 吕良敬. 系统性红斑狼疮CAR T细胞治疗疗效预测及安全性评估的潜在生物标志物[J]. 诊断学理论与实践, 2024, 23(03): 263-269. |
[2] | 汤建平, 龚邦东. 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022, 21(03): 291-298. |
[3] | 史玉玲. 英国《皮肤科医师协会银屑病生物制剂治疗指南》(2020版)解读[J]. 诊断学理论与实践, 2021, 20(01): 37-42. |
[4] | 葛建华, 龚文, 施新明, 巩惠芸, 马龙新, 周劲峰, 石慧. ELISA法联合CLIFT法检测抗双链DNA-IgG抗体应用于系统性红斑狼疮的诊断价值[J]. 诊断学理论与实践, 2018, 17(06): 658-663. |
[5] | 奚慧琴, 金艳, 潘蕾, 沈晓炜. 系统性红斑狼疮患者疾病活动性评估及监测[J]. 诊断学理论与实践, 2018, 17(05): 616-619. |
[6] | 扶琼, 吕良敬. 1971年到2017年系统性红斑狼疮分类标准的发展和比较[J]. 诊断学理论与实践, 2018, 17(03): 249-253. |
[7] | 龚邦东, 汤建平. 干燥综合征分类标准的时代演化及对临床诊断的指导价值[J]. 诊断学理论与实践, 2018, 17(03): 244-248. |
[8] | 卢红娟, 吴歆, 周凌, 赵娟, 徐沪济. 强直性脊柱炎合并系统性红斑狼疮病例报告1例[J]. 诊断学理论与实践, 2018, 17(03): 341-343. |
[9] | 陆一闻, 潘秀军, 郑英霞, 沈立松,. 系统性红斑狼疮患者的白细胞介素17阳性调节性T细胞对B细胞的存活及抗体分泌的调节[J]. 诊断学理论与实践, 2015, 14(06): 528-532. |
[10] | 李卫平, 施若非,. 抗核抗体谱检测在系统性红斑狼疮诊断中的临床价值[J]. 诊断学理论与实践, 2015, 14(06): 545-548. |
[11] | 马建芳, 孙治坤, 潘萌, 李根, 汤荟冬,. 系统性红斑狼疮的中枢神经系统表现特征[J]. 诊断学理论与实践, 2015, 14(03): 229-234. |
[12] | 杨希, 姜波, 冯学兵, 姚根宏, 孙凌云,. 间充质干细胞调控趋化因子配体2对系统性红斑狼疮作用的机制探讨[J]. 诊断学理论与实践, 2014, 13(03): 246-250. |
[13] | 周盈盈, 周桢源, 黄新芳, 沈南,. miR-363-3p促进人浆细胞样树突细胞干扰素α分泌的机制研究[J]. 诊断学理论与实践, 2014, 13(03): 255-259. |
[14] | 胡亮, 彭奕冰, 王学锋, 巩惠芸,. 系统性红斑狼疮患者外周血MMP-2、MMP-3、MMP-9和TIMP-4水平的检测及其临床意义[J]. 诊断学理论与实践, 2012, 11(04): 397-400. |
[15] | 干倩, 张凤如,. 系统性红斑狼疮合并冠状动脉内急性血栓形成一例[J]. 诊断学理论与实践, 2011, 10(01): 68-69. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||